Defining better intervention strategies for individuals diagnosed with aggressive cancers.

Our Focus

A translational research department providing therapeutic and diagnostic development capabilities focused on the evaluation and application of emerging technologies in cancer care.

By conducting research to obtain a better understanding of disease classification and targeted therapies, Experimental Therapeutics (ET) endeavors to define better intervention strategies for individuals with aggressive cancers. ET is well respected internationally for its track record of proficiency and efficiency when linking preclinical and clinical research, and is focused on the critical need to rapidly establish the therapeutic value of emerging technologies through validated assessments in preclinical models of cancer and in patients.

What We Do

Experimental Therapeutics has a variety of drug development capabilities, including preclinical models (cell-based and animal-model based models) and formal capabilities to support some GLP studies (Rodent GLP) and GMP manufacturing. Our research ranges from development of nanomedicines to identification of unique, targetable, proteins in cells. 

News & Events

Research Labs & Principal Investigators

Recent Publications

Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.

Cancer research, 2023
Chou, Jonathan, Egusa, Emily A, Wang, Sinan, Badura, Michelle L, Lee, Fei, Bidkar, Anil P, Zhu, Jun, Shenoy, Tanushree, Trepka, Kai, Robinson, Troy M, Steri, Veronica, Huang, Jiaoti, Wang, Yuzhuo, Small, Eric J, Chan, Emily, Stohr, Bradley A, Ashworth, Alan, Delafontaine, Brant, Rottey, Sylvie, Cooke, Keegan S, Hashemi Sadraei, Nooshin, Yu, Brian, Salvati, Mark, Bailis, Julie M, Feng, Felix Y, Flavell, Robert R, Aggarwal, Rahul
Back to top